EcoR1 Raises Its Zymeworks Stake to 22.61%

EcoR1 Capital, a biotech-focused hedge fund, made waves today with a substantial Form 4 filing.

The fund reported a purchase of $2,278,811 worth of Zymeworks $ZYME, increasing its ownership stake to 22.61%.

It’s worth noting that EcoR1 has a strong track record of identifying winners in the biotech space, often making concentrated bets on companies with transformative pipelines or innovative therapies.

Here’s The Hot Corner, with data from January 15, 2025:

On another note, Phillip Frost, CEO of OPKO Health Inc $OPK, disclosed the acquisition of 500,000 shares, continuing a pattern of insider buying.